Pfizer’s breast cancer drug palbociclib has an FDA review date. The company announced Monday that the Breakthrough Therapy breast cancer drug will get a regulatory yea or nay by April 13, 2015. The experimental drug is being reviewed for postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment.
The company’s announcement is just two months after the August filing date it anticipated in its second-quarter earnings call. The drug is partly of note because it could be a foundational one were Pfizer to break up into three independent units after 2017.
